NCT06003218Completed
Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation
Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 2 Apr 2025
Brief summary (registry, in English)
Percutaneous radiofrequency ablation is a commonly treatment for patients with liver cancer that cannot be surgically resected. During the procedure, patients need to keep awake and cooperate with the procedure, including deep breath and hold breath. However, intolerable pain generated during puncture and radiofrequency heating may cause body movements and interfere the procedure. Oxycodone is frequently used for analgesia but still insufficient. A recent study showed that dexmedetomidine-esketamine combination improves analgesia without increasing adverse events. After stopping infusion, the analgesic/sleep-promoting effects of dexmedetomidine-esketamine seemed to last for up to 24 hours. The investigators hypothesize that dexmedetomidine-esketamine combination as a supplement to oxycodone will improve sedation and analgesia in patients undergoing radiofrequency liver ablation of the liver.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 88 (actual)
- First submitted
- 12 Aug 2023
- Start date
- 16 Oct 2023
- Primary completion date
- 26 Sept 2024
- Lead sponsor
- Peking University First Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06003218
What you commit to
- Study type: Interventional
- Participants enrolled: 88
- From 16 Oct 2023 to the primary completion date, 26 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Diagnosed obstructive sleep apnea (OSA) or judged to be at high-risk of moderate-to-severe OSA before surgery.
- Severe liver dysfunction (Child-Pugh grade C), severe renal dysfunction (dialysis before surgery), or classified as American Society of Anesthesiologists (ASA) grade \>III before surgery.
Other illness
- Diagnosed schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis before surgery.
- Inability to communicate due to coma, severe dementia, or language barrier before surgery.
- Allergy to any drug used during the study, or other conditions that are considered unsuitable for study participation.
Lab values
- Preoperative left ventricular ejection fraction (LVEF) \<30%, or those with sick sinus syndrome, sinus bradycardia (heart rate \<50 beats per minute), or atrioventricular block at grade II or above without pacemaker.
Other
- Refused to participate.
Who the study is looking for
- Aged ≥18 years but ≤85 years.
- Scheduled for elective ultrasound-guided percutaneous radiofrequency ablation for primary or metastatic liver cancer.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.